{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:15:54Z","timestamp":1792624554883,"version":"4.5.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diabetic retinopathy (DR), substantially impacts the quality of life of diabetic patients, it remains, in developed countries, the leading cause of vision loss in working-age adults (20\u201365 years). Currently, about 90 million diabetics suffer from DR. DR is a silent complication that in its early stages is asymptomatic. However, over time, chronic hyperglycemia can lead to sensitive retinal damage, leading to fluid accumulation and retinal haemorrhage (HM), resulting in cloudy or blurred vision. It can, therefore, lead to severe visual impairment or even blindness if left untreated. It can be classified into nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is featured with intraretinal microvasculature changes and can be further divided into mild, moderate, and severe stages that may associate with diabetic macular oedema (DME). PDR involves the formation and growth of new blood vessels (retinal neovascularisation) under low oxygen conditions. Early identification and treatment are key priorities for reducing the morbidity of diabetic eye disease. In the early stages of DR, a tight control of glycemia, blood pressure, plasma lipids, and regular monitoring can help prevent its progression to more advanced stages. In advanced stages, the main treatments of DR include intraocular injections of anti-vascular endothelial growth factor (VEGF) antibodies, laser treatments, and vitrectomy. The aim of this review is to provide a comprehensive overview of the published literature pertaining to the latest progress in the treatment of DR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_480_21","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:22:18Z","timestamp":1654474938000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":60,"title":["Diabetic Retinopathy"],"prefix":"10.4103","volume":"26","author":[{"given":"Bassirou A. M.","family":"Mounirou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouhou D.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abba K. H.","family":"Yakoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamane S. M.","family":"Aminou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240828","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","article-title":"Diabetic retinopathy","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"key":"R2-4-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jdiacomp.2006.08.002","article-title":"Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy","volume":"21","author":"Candrilli","year":"2007","journal-title":"J Diabetes Complications"},{"key":"R3-4-20240828","doi-asserted-by":"crossref","first-page":"801269","DOI":"10.1155\/2014\/801269","article-title":"Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets","volume":"2014","author":"Safi","year":"2014","journal-title":"Biomed Res Int"},{"key":"R4-4-20240828","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"R5-4-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9080705","article-title":"Extracellular vesicles and microrna:Putative role in diagnosis and treatment of diabetic retinopathy","volume":"9","author":"Martins","year":"2020","journal-title":"Antioxidants"},{"key":"R6-4-20240828","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4103\/0019-5359.48562","article-title":"Diabetic retinopathy:A comprehensive review","volume":"62","author":"Shah","year":"2008","journal-title":"Indian J Med Sci"},{"key":"R7-4-20240828","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0975-3583.83035","article-title":"Inflammation and diabetic retinal microvascular complications","volume":"2","author":"Zhang","year":"2011","journal-title":"J Cardiovasc Dis Res"},{"key":"R8-4-20240828","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-9233.154388","article-title":"Diabetic retinopathy and systemic factors","volume":"22","author":"Frank","year":"2015","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R9-4-20240828","first-page":"303","article-title":"r. The natural history of diabetic retinopathy","volume":"37","author":"Burditt","year":"1968","journal-title":"QJM Int J Med"},{"key":"R10-4-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/sym11060749","article-title":"Recent development on detection methods for the diagnosis of diabetic retinopathy","volume":"11","author":"QureshiI","year":"2019","journal-title":"Symmetry"},{"key":"R11-4-20240828","first-page":"1","article-title":"Current advances in pharmacotherapy and technology for diabetic retinopathy:A systematic review","volume":"2018","author":"Lu","year":"2018","journal-title":"J Ophthalmol"},{"key":"R12-4-20240828","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/eye.2017.64","article-title":"Oxidative stress and diabetic retinopathy:Development and treatment","volume":"31","author":"Calderon","year":"2017","journal-title":"Eye (Basingstoke"},{"key":"R13-4-20240828","doi-asserted-by":"crossref","first-page":"4940825","DOI":"10.1155\/2019\/4940825","article-title":"Oxidative stress and microvascular alterations in diabetic retinopathy:Future therapies","volume":"2019","author":"Rodriguez","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"R14-4-20240828","doi-asserted-by":"crossref","first-page":"343560","DOI":"10.1155\/2013\/343560","article-title":"Pathophysiology of diabetic retinopathy","volume":"2013","author":"Tarr","year":"2013","journal-title":"ISRN Ophthalmol"},{"key":"R15-4-20240828","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/0022-3859.97176","article-title":"Current trends in the pharmacotherapy ofdiabetic retinopathy","volume":"58","author":"Kumar","year":"2012","journal-title":"J Postgr Med"},{"key":"R16-4-20240828","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"Banting Lecture 2004. The pathobiology of diabetic complications. A unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"R17-4-20240828","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R18-4-20240828","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI2425","article-title":"Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin","volume":"102","author":"Barber","year":"1998","journal-title":"J Clin Invest"},{"key":"R19-4-20240828","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.2337\/dc07-0332","article-title":"Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration","volume":"30","author":"Carrasco","year":"2007","journal-title":"Diabetes Care"},{"key":"R20-4-20240828","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00125-009-1548-8","article-title":"Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy","volume":"52","author":"Garcia-Ram\u00edrez","year":"2009","journal-title":"Diabetologia"},{"key":"R21-4-20240828","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1126\/science.1957169","article-title":"Optical coherence tomography","volume":"254","author":"Huang","year":"1991","journal-title":"Science"},{"key":"R22-4-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/ijo.IJO_902_17","article-title":"Optical coherence tomography:A guide to interpretation of common macular diseases","volume":"66","author":"Bhende","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R23-4-20240828","first-page":"141","article-title":"Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus","volume":"6","author":"Zhu","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"R24-4-20240828","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.2337\/diabetes.55.04.06.db05-0744","article-title":"Diabetes reduces basal retinal insulin receptor signaling:Reversal with systemic and local insulin","volume":"55","author":"Reiter","year":"2006","journal-title":"Diabetes"},{"key":"R25-4-20240828","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00125-011-2149-x","article-title":"Retinal function in relation to improved glycaemic control in type 1 diabetes","volume":"54","author":"Holfort","year":"2011","journal-title":"Diabetologia"},{"key":"R26-4-20240828","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/dom.12384","article-title":"New treatments for diabetic retinopathy","volume":"17","author":"Das","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R28-4-20240828","first-page":"54","article-title":"Diabetic retinopathy \u2014update on prevention techniques, present therapies, and new leads","volume":"7","author":"Marozas","year":"2014","journal-title":"US Ophthalmic Rev"},{"key":"R29-4-20240828","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"R30-4-20240828","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1631\/jzus.B1200237","article-title":"Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients","volume":"14","author":"Zhang","year":"2013","journal-title":"J Zhejiang Univ Sci B"},{"key":"R31-4-20240828","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1167\/iovs.11-7598","article-title":"Differential association of serum lipids with diabetic retinopathy and diabetic macular edema","volume":"52","author":"Benarous","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-4-20240828","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy:A systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"key":"R33-4-20240828","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcjo.2014.12.014","article-title":"Efficacy\/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME","volume":"50","author":"Berger","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"R34-4-20240828","doi-asserted-by":"crossref","first-page":"e115797","DOI":"10.1371\/journal.pone.0115797","article-title":"Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema:A meta-analysis of randomized controlled trials","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"R35-4-20240828","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL study:Ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"key":"R36-4-20240828","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/OPTH.S236637","article-title":"The evolving treatment of diabetic retinopathy","volume":"14","author":"Mansour","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R37-4-20240828","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","article-title":"Treatment of diabetic retinopathy:Recent advances and unresolved challenges","volume":"7","author":"Stewart","year":"2016","journal-title":"World J Diabetes"},{"key":"R38-4-20240828","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3928\/1542-8877-19991101-03","article-title":"Subthreshold (invisible) modified grid diode laser photocoagulation and diffuse diabetic macular edema (DDME)","volume":"30","author":"Friberg","year":"1999","journal-title":"Ophthalmic Surg Lasers"},{"key":"R39-4-20240828","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3928\/1542-8877-19991101-04","article-title":"Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME)","volume":"30","author":"Akduman","year":"1999","journal-title":"Ophthalmic Surg Lasers"},{"key":"R40-4-20240828","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1076\/soph.16.1.19.4217","article-title":"Infrared micropulsed laser treatment for diabetic macular edema\u2013subthreshold versus threshold lesions","volume":"16","author":"Friberg","year":"2001","journal-title":"Semin Ophthalmol"},{"key":"R41-4-20240828","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/bjo.2003.040949","article-title":"Subthreshold micropulse diode laser treatment in diabetic macular oedema","volume":"88","author":"Laursen","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R42-4-20240828","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1076\/soph.18.3.147.29812","article-title":"Subthreshold and micropulse diode laser photocoagulation","volume":"18","author":"Dorin","year":"2003","journal-title":"Semin Ophthalmol"},{"key":"R43-4-20240828","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bjo.2004.051540","article-title":"Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema","volume":"89","author":"Luttrull","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R44-4-20240828","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1152\/japplphysiol.01267.2001","article-title":"Heat shock proteins:Modifying factors in physiological stress responses and acquired thermotolerance","volume":"92","author":"Kregel","year":"2002","journal-title":"J Appl Physiol"},{"key":"R45-4-20240828","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exer.2014.04.014","article-title":"Protective effect of a laser-induced sub-lethal temperature rise on RPE cells from oxidative stress","volume":"124","author":"Iwami","year":"2014","journal-title":"Exp Eye Res"},{"key":"R46-4-20240828","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1442-9071.2007.01566.x","article-title":"Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema:A three-year follow up","volume":"35","author":"Sivaprasad","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R47-4-20240828","first-page":"469","article-title":"VEGF and PEDF secretions over time following various laser irradiations on an RPE organ culture","volume":"51","author":"Miura","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R48-4-20240828","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1167\/iovs.10-5917","article-title":"Non-damaging retinal phototherapy:Dynamic range of heat shock protein expression","volume":"52","author":"Sramek","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R49-4-20240828","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/eye.2008.416","article-title":"Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy","volume":"23","author":"Kumar","year":"2009","journal-title":"Eye"},{"key":"R50-4-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erd.12.1","article-title":"Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema","volume":"9","author":"Sivaprasad","year":"2012","journal-title":"Expert Rev Med Devices"},{"key":"R51-4-20240828","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/157339912800840523","article-title":"Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema:A review","volume":"8","author":"Luttrull","year":"2012","journal-title":"Curr Diabetes Rev"},{"key":"R52-4-20240828","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00417-014-2845-6","article-title":"Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment","volume":"253","author":"Parodi","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R53-4-20240828","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/09298673113209990030","article-title":"Subthreshold laser therapy for diabetic macular edema:Metabolic and safety issues","volume":"20","author":"Vujosevic","year":"2013","journal-title":"Curr Med Chem"},{"key":"R54-4-20240828","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1097\/IAE.0000000000000177","article-title":"Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity","volume":"34","author":"Luttrull","year":"2014","journal-title":"Retina"},{"key":"R55-4-20240828","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1167\/iovs.10-6828","article-title":"Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema","volume":"52","author":"Lavinsky","year":"2011","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R56-4-20240828","first-page":"CD012314","article-title":"Different lasers and techniques for proliferative diabetic retinopathy","volume":"3","author":"Moutray","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-4-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IAE.0b013e3182993edc","article-title":"Subvisible retinal laser therapy:Titration algorithm and tissue response","volume":"34","author":"Lavinsky","year":"2014","journal-title":"Retina"},{"key":"R58-4-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/OPTH.S27859","article-title":"Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas)","volume":"6","author":"Kernt","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R59-4-20240828","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ophtha.2010.10.007","article-title":"Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS","volume":"118","author":"Kozak","year":"2011","journal-title":"Ophthalmology"},{"key":"R60-4-20240828","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/IAE.0b013e318227ab5b","article-title":"Focal navigated laser photocoagulation in retinovascular disease:Clinical results in initial case series","volume":"32","author":"Kozak","year":"2012","journal-title":"Retina"},{"key":"R61-4-20240828","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2012-302189","article-title":"Pilot randomised clinical trial of Pascal TargETEd retinal versus variable fluence PANretinal 20 ms laser in diabetic retinopathy:PETER PAN study","volume":"97","author":"Muqit","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R62-4-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/EB.S69185","article-title":"Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy:Current status and future prospects","volume":"8","author":"Saxena","year":"2016","journal-title":"Eye Brain"},{"key":"R63-4-20240828","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/dc09-0565","article-title":"Advances in the medical treatment of diabetic retinopathy","volume":"32","author":"Sim\u00f3","year":"2009","journal-title":"Diabetes Care"},{"key":"R64-4-20240828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1755-3768.2010.02010.x","article-title":"Treatment of diabetic retinopathy with anti-VEGF drugs","volume":"89","author":"Waisbourd","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"R66-4-20240828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0301-4738.178154","article-title":"Novel pharmacotherapies in diabetic retinopathy:Current status and what's in the horizon?","volume":"64","author":"Das","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R67-4-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ophtha.2018.08.001","article-title":"Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"key":"R69-4-20240828","first-page":"75","article-title":"Diabetic retinopathy:Early diagnosis and effective treatment","volume":"107","author":"Kollias","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"R70-4-20240828","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1165\/ajrcmb.16.4.9115750","article-title":"Induction of vascular endothelial growth factor by plateletactivating factor and platelet-derived growth factor is downregulated by corticosteroids","volume":"16","author":"Nauck","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R71-4-20240828","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1167\/iovs.04-0905","article-title":"Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina, Invest","volume":"46","author":"Tamura","year":"2005","journal-title":"Ophthalmol Vis Sci"},{"key":"R73-4-20240828","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.addr.2021.04.007","article-title":"Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis","volume":"173","author":"Silva","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"R74-4-20240828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00006982-200602000-00002","article-title":"Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema","volume":"26","author":"Zein","year":"2006","journal-title":"Retina"},{"key":"R75-4-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.124.5.643","article-title":"Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy","volume":"124","author":"Bandello","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R76-4-20240828","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00006982-200502000-00003","article-title":"Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy","volume":"25","author":"Zacks","year":"2005","journal-title":"Retina"},{"key":"R77-4-20240828","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s00417-004-0911-1","article-title":"Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy","volume":"242","author":"Bandello","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R78-4-20240828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ajo.2008.08.024","article-title":"Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema:One-year results of a randomized clinical trial","volume":"147","author":"Maia","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R79-4-20240828","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema","volume":"115","author":"Maia","year":"2008","journal-title":"Ophthalmology"},{"key":"R80-4-20240828","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/IAE.0b013e31818144a7","article-title":"A randomized trial comparing intravitreal triamcinolone and focal\/grid photocoagulation for diabetic macular edema:Baseline features","volume":"28","author":"Ip","year":"2008","journal-title":"Retina"},{"key":"R81-4-20240828","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","article-title":"Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema","volume":"127","author":"Beck","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R82-4-20240828","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"R83-4-20240828","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"key":"R84-4-20240828","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ophtha.2010.09.029","article-title":"Intravitreal triamcinolone prior to laser treatment of diabetic macular edema:24-month results of a randomized controlled trial","volume":"118","author":"Gillies","year":"2011","journal-title":"Ophthalmology"},{"key":"R85-4-20240828","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IAE.0b013e3181b4f125","article-title":"Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema","volume":"30","author":"Mirshahi","year":"2010","journal-title":"Retina"},{"key":"R86-4-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1167\/iovs.05-0531","article-title":"Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage","volume":"47","author":"Amrite","year":"2006","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R87-4-20240828","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2337\/db05-1621","article-title":"Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology","volume":"56","author":"Kern","year":"2007","journal-title":"Diabetes"},{"key":"R88-4-20240828","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1167\/iovs.08-1755","article-title":"Role of NADPH oxidase in retinal vascular inflammation","volume":"49","author":"Al-Shabrawey","year":"2008","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R89-4-20240828","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1167\/iovs.08-2676","article-title":"NAD (P) H oxidase-dependent regulation of CCL2 production during retinal inflammation","volume":"50","author":"Zhang","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R90-4-20240828","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/10715760310001604189","article-title":"Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants","volume":"37","author":"Kowluru","year":"2003","journal-title":"Free Radic Res"},{"key":"R91-4-20240828","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","article-title":"Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats","volume":"1842","author":"Goncalves","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R92-4-20240828","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.biopha.2018.03.144","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation","volume":"102","author":"Goncalves","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R93-4-20240828","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1463-1326.2011.01548.x","article-title":"Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model","volume":"14","author":"Goncalves","year":"2012","journal-title":"Diabetes Obes. Metab"},{"key":"R94-4-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hernandez","year":"2016","journal-title":"Diabetes"},{"key":"R95-4-20240828","doi-asserted-by":"crossref","first-page":"e6567","DOI":"10.7717\/peerj.6567","article-title":"A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats","volume":"7","author":"Zhang","year":"2019","journal-title":"Peer J"},{"key":"R96-4-20240828","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejphar.2019.04.038","article-title":"Diabetic retinopathy:Focus on NADPH oxidase and its potential as therapeutic target","volume":"853","author":"Peng","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"R97-4-20240828","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/ijms19061816","article-title":"Diabetic retinopathy:Pathophysiology and treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R98-4-20240828","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.diabet.2019.04.002","article-title":"Diabetic retinopathy, a vascular and inflammatory disease:Therapeutic implications","volume":"45","author":"Semeraro","year":"2019","journal-title":"Diabetes Metab"},{"key":"R99-4-20240828","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/nu11040771","article-title":"Nutraceuticals for the treatment of diabetic retinopathy","volume":"11","author":"Rossino","year":"2019","journal-title":"Nutrients"},{"key":"R100-4-20240828","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/02713683.2017.1319491","article-title":"Protective effect of intravitreal administration of exosomes derived from mesenchymal stem cells on retinal ischemia","volume":"42","author":"Moisseiev","year":"2017","journal-title":"Curr Eye Res"},{"key":"R101-4-20240828","doi-asserted-by":"crossref","first-page":"34562","DOI":"10.1038\/srep34562","article-title":"Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"R103-4-20240828","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1167\/iovs.18-25617","article-title":"Exosomes derived from mesenchymal stem cells modulate miR-126 to ameliorate hyperglycemia-induced retinal inflammation via targeting HMGB1","volume":"60","author":"Zhang","year":"2019","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R104-4-20240828","doi-asserted-by":"crossref","first-page":"28058","DOI":"10.1074\/jbc.M113.470765","article-title":"Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization","volume":"288","author":"Hajrasouliha","year":"2013","journal-title":"J Biol Chem"},{"key":"R105-4-20240828","doi-asserted-by":"crossref","first-page":"30742","DOI":"10.1038\/srep30742","article-title":"cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness","volume":"6","author":"Wiley","year":"2006","journal-title":"Sci Rep"},{"key":"R106-4-20240828","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.biomaterials.2006.06.035","article-title":"Co-culture of human embryonic stem cells with murine embryonic fibroblasts on microwell-patterned substrates","volume":"27","author":"Khademhosseini","year":"2006","journal-title":"Biomaterials"},{"key":"R107-4-20240828","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ICU.0b013e328329b5f2","article-title":"Stem-cell therapy in retinal disease","volume":"20","author":"Baker","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"R108-4-20240828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/jcm4040567","article-title":"Patient-specific iPSC-derived RPE for modeling of retinal diseases","volume":"4","author":"Nguyen","year":"2015","journal-title":"J Clin Med"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_480_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:58:37Z","timestamp":1787756317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_480_21"}},"subtitle":["An Overview of Treatments"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_480_21","relation":{},"ISSN":["2230-9500"],"issn-type":[{"value":"2230-9500","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}